WA
ALNY icon

Winfield Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

Winfield Associates’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5
Closed -$1K – 140
2017
Q4 		$1K Hold
5
– – ﹤0.01% 730
2017
Q3 		$1K Hold
5
– – ﹤0.01% 658
2017
Q2 		$0 Hold
5
– – ﹤0.01% 866
2017
Q1 		$0 Sell
5
-10
-67% -$462 ﹤0.01% 748
2016
Q4 		$1K Sell
15
-5
-25% -$209 ﹤0.01% 600
2016
Q3 		$1K Hold
20
– – ﹤0.01% 581
2016
Q2 		$1K Buy
+20
New +$1.26K ﹤0.01% 576

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Winfield Associates's ALNY Position: Q1 2018 in Review

Winfield Associates sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2018, closing a stake of 5 shares — an estimated $1K sold.

Winfield Associates first reported a position in ALNY in Q2 2016 and held it in 7 quarters. The position peaked at $1K in Q4 2017. 293 funds tracked by Wall St. Rank hold ALNY as of Q1 2018.

  • Winfield Associates reported no remaining Alnylam Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Winfield Associates sold 5 Alnylam Pharmaceuticals shares in Q1 2018, an estimated $1K.
  • Winfield Associates first reported a position in Alnylam Pharmaceuticals in Q2 2016 and held it in 7 quarters.
  • Winfield Associates's Alnylam Pharmaceuticals position peaked at $1K in Q4 2017.
  • 293 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.